Novo Nordisk has begun phase III trial with antibody

Last summer, Novo Nordisk acquired the US-based biotech company Corvidia Therapeutics to access the antibody ziltivekimab. The pharmaceutical company has now commenced a phase III study of the drug, the company confirms in comment to MedWatch.

Photo: Stine Tidsvilde

In the beginning of September, Novo Nordisk started a phase III with the antibody ziltivekimab, which the company received in a million-dollar acquisition of the US-based company Corvidia Therapeutics last year, according to database, which collects information about clinical studies, and Novo Nordisk confirms as much in comment to MedWatch.

According to the database, Novo Nordisk's intention with the phase III study, which has been named Zeus, is to test whether the substance ziltivekimab can reduce risk of cardiovascular events, such as heart attacks and strokes, in people suffering from cardiovascular disease, chronic kidney disease and inflammation.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs